LivaNova (NASDAQ:LIVN) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of LivaNova (NASDAQ:LIVN) from a buy rating to a strong-buy rating in a research report released on Saturday morning.

LIVN has been the topic of several other research reports. Robert W. Baird set a $75.00 target price on shares of LivaNova in a research note on Tuesday. The Goldman Sachs Group set a $55.00 target price on LivaNova and gave the stock a “neutral” rating in a report on Wednesday, October 1st. Mizuho raised their target price on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of LivaNova in a research report on Wednesday, September 3rd. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 15th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.63.

LivaNova Trading Up 1.2%

Shares of LIVN opened at $62.82 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.12 and a debt-to-equity ratio of 0.30. The stock has a market cap of $3.43 billion, a PE ratio of -15.70 and a beta of 1.02. LivaNova has a 1 year low of $32.48 and a 1 year high of $65.57. The stock has a 50 day simple moving average of $57.31 and a 200-day simple moving average of $52.26.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in shares of LivaNova by 182.5% during the second quarter. GAMMA Investing LLC now owns 630 shares of the company’s stock worth $28,000 after purchasing an additional 407 shares during the period. State of Wyoming bought a new position in LivaNova during the second quarter worth about $31,000. EverSource Wealth Advisors LLC boosted its holdings in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares during the last quarter. Quarry LP acquired a new position in shares of LivaNova during the 3rd quarter worth about $36,000. Finally, UMB Bank n.a. increased its stake in shares of LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after acquiring an additional 306 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.